TSTickerStar
Company alerts/DARE
DARE company alerts

DARE updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for DARE. Subscribe to DARE alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent DARE alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

Daré Bioscience Reports Q3 2026 Financial Results

Daré Bioscience reported Q3 2026 revenue of approximately $48,000 compared to approximately $2,300 in Q3 2025, with the increase attributable to research and development services revenue under Gates Foundation agreements and initial Flora Sync LF5 sales that began in July 2026. Net loss improved to approximately $3.2 million from approximately $3.6 million in the prior year period, while EPS improved to $(0.18) from $(0.28). The company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q4...

Read source-backed brief
SEC filingSEC filing

DARE 10-Q filed 2026-11-16 | Key takeaways

DARE filed its 10-Q; the most relevant disclosure change is expanded Nasdaq listing compliance: Company faces delisting risk after receiving delisting determination letter July 13, 2026 for stockholders' equity below $2.5M; received letter October 26, 2026 finding compliance based on August 2026 financing but with heightened quarterly equity requirements.

Read source-backed brief